Guilford, Connecticut and Rochester, New York – (work wire) – Butterfly Network, Inc. (NYSE: BFLY), a digital health company transforming care through next-generation point-of-care ultrasound (“POCUS”), and the University of Rochester Medical Center (URMC), upstate New York’s largest and most comprehensive healthcare system, announced today that The organizations will work together to bring Butterfly Blueprint™, a system-wide ultrasound platform, to URMC.
“Our evolving relationship with Butterfly will provide a unique opportunity to leverage URMC’s clinical and academic expertise in collaboration with an innovative health technology company to advance the boundaries of bedside decision-making, said Dr. Michael F. Rotondo, CEO of the University of Rochester Group of Medical Schools and Vice Dean for Clinical Affairs in the university’s School of Medicine and Dentistry. “By working alongside Butterfly, research teams across the university can explore the potential of image data acquisition and AI deployment to improve patient care, medical education and clinical management. ”
Verified research shows that point-of-care ultrasound improves initial diagnostic accuracy and can reduce downstream referrals and imaging costs. In addition, the use of bedside imaging as part of the initial assessment in a primary care setting led to a change in diagnosis in 49.4% of patients and a change in care management across 50.9%1.
“The vast majority of care decisions are made with incomplete information. With Butterfly, vision is knowledge, and the benefit of having an accessible, easy-to-use, AI-enabled imaging tool in every practitioner’s pocket means that better, more informed decisions can be made earlier in care, every time,” said Dr. Todd Fruchterman, President of the Butterfly Network. Butterfly and CEO.”The University of Rochester Medical Center is a leader in healthcare excellence; We are pleased to partner with them to transform care decision-making and demonstrate the power of point-of-care ultrasound powered by artificial intelligence across the enterprise. We believe the leadership of URMC and other organizations committed to advancing medicine through technology, education, and the power of artificial intelligence, will create a new standard of care.”
“said Dr. David L. Waldman, President of Medical Information Technology Development and former Head of Imaging Sciences at URMC. “Deploying ultrasound at the point of care in the enterprise will eventually enable every clinician, in all departments, to quickly image patients where they are.”
URMC officials said they expect to roll out the Butterfly Blueprint™ and begin employee education this summer, and will begin providing the company’s portable imaging units this fall to second- and third-year medical students, UR Medicine primary care providers, and UR Medicine Home Care nurses. In planned future phases, URMC and Butterfly Network expect to pursue multiple research projects to explore and validate the use of Butterfly Blueprint™ across the enterprise. Innovative image analysis, artificial intelligence, and clinical pathways will be key aspects of the research. Clinical focus areas will include education and curricula for point-of-care ultrasound, creating encounter-based workflows, developing best practices for system deployment, infrastructure integration, compliance, quality assurance, and 3D procedural guidance.
To learn more about Butterfly technology and to view a demonstration of Butterfly iQ+, the first full-body single-sensor handheld ultrasound system using semiconductor technology, please visit: https://www.butterflynetwork.com/. For more information about the University of Rochester Medical Center, visit https://www.urmc.rochester.edu.
About the University of Rochester Medical Center
URMC is one of the nation’s leading academic medical centers, and forms the cornerstone of the University of Rochester’s health research, education, and patient care. The university’s College of Medicine and Dentistry is among the top quartile of US medical centers in federal research funding. As a leading healthcare delivery network in upstate New York, patients benefit from the medical center’s strong biomedical education and research programs, and its position as a nationally recognized leader in digital health and innovation. The university’s healthcare delivery network is anchored by Strong Memorial Hospital, a university-owned 886-bed teaching hospital designated by the New York State Department of Health as a regional center for level I trauma and burns and home to Western New York’s only heart transplant program. With more than 26,000 part- and full-time employees, the medical center is the single largest component of a leading employer in the Rochester area. For more information, visit URMC at https://www.urmc.rochester.edu/.
About Butterfly Network
Founded by Dr. Jonathan Rothberg in 2011, it was recently listed on the New York Stock Exchange through a business group with Longview Acquisition Corp. Butterfly has created the first handheld ultrasound system and a single whole-body probe using semiconductor technology, Butterfly iQ+. Butterfly’s mission is to democratize medical imaging and contribute to the aspiration of global health equality, making high-quality ultrasound affordable, easy to use, globally accessible and intelligently connected, including the 4.7 billion people around the world who lack access to Ultrasound . With its proprietary Ultrasound-on-Chip™ technology, Butterfly is paving the way for early detection and remote management of health conditions around the world. Butterfly iQ+ can be purchased online today by healthcare practitioners in the United States, Australia, Austria, Belgium, Canada, Denmark, Finland, France, Germany, Ireland, Italy, Netherlands, New Zealand, Norway, Poland, Portugal, Spain, Sweden, Switzerland and the United Kingdom.
Butterfly Blueprint™ supports healthcare systems by giving them access to new and diagnostically meaningful clinical information at the bedside while helping to support procedure availability and utility across care settings. By pairing the world’s first easy-to-use, hand-held full-body ultrasound probe with an intuitive, mobile workflow first unlocks powerful new uses for ultrasound across the continuum of care—it does for imaging what a stethoscope did for auscultation. This solution is enabled by a dedicated customer experience team and proven processes that include solution consulting, implementation services and post support.
The Butterfly iQ+ probe is a prescription device intended for trained healthcare professionals only.
Butterfly Network, Inc. Forward-Looking Statements This press release includes “forward-looking statements” within the meaning of the “safe harbor” provisions of the US Securities Litigation Reform Act of 1995. Butterfly’s actual results may differ from its expectations, estimates, and expectations, and therefore, you should not rely on these forward-looking statements as predictions. for future events. Words like “expect,” “estimate,” “project,” “budget,” “expect,” “expect,” “intend,” “plan,” “may,” “will,” “could,” “should,” aim “believe,” “predict,” “potential,” “continue,” and similar expressions (or negative versions of such words or expressions) limit such forward-looking statements. These forward-looking statements include, but are not limited to, Butterfly’s goals and expectations with respect to its strategic partnership with the University of Rochester Medical Center, Butterfly’s development and marketing efforts, and “About Butterfly Network” business plans. These forward-looking statements involve significant risks and uncertainties that could cause actual results to differ materially from those discussed in the forward-looking statements. Most of these factors are beyond the butterfly’s control and are difficult to predict. Factors that may cause such differences include, but are not limited to: the impact of COVID-19 on Butterfly’s business; Ability to recognize the expected benefits from merging its business with Longview Acquisition Corp. Butterfly’s ability to grow and profitably manage growth; the success, cost, and timing of Butterfly’s product and service development activities; Features and potential benefits of Butterfly products and services; Butterfly’s ability to obtain and maintain regulatory approval for its products, and any relevant restrictions and limitations of any approved product; Butterfly’s ability to identify, license or acquire additional technology; Butterfly’s ability to maintain existing licensing, manufacturing, supply and distribution agreements; Butterfly’s ability to compete with other companies that are currently marketing or participating in the development of products and services that Butterfly is currently marketing or developing; changes in applicable laws or regulations; the size and growth potential of the Butterfly product and service markets, and its ability to serve those markets, either alone or in partnership with others; Prices for Butterfly’s products and services and reimbursement for medical procedures performed using its products and services; Butterfly estimates regarding expenditures, revenue, capital requirements, and needs for additional financing; Butterfly’s financial performance; Butterfly’s ability to raise finances in the future; and other risks and uncertainties referred to from time to time in Butterfly’s filings with the Securities and Exchange Commission. Butterfly warns that the list of the above factors is not exhaustive. Butterfly cautions you not to place undue reliance on any forward-looking statements, which speak only as of the date of this press release. Butterfly does not undertake or accept any obligation or undertake to publicly disclose any updates or revisions to any forward-looking statements to reflect any change in Butterfly’s expectations or any change in events, circumstances or conditions on which such statement is based.
1Dear Andersen C, Brodersen J, Davidsen AS, et
The use and impact of point-of-care ultrasound in general practice: an observational study
BMJ is open 2020;10:e037664. doi: 10.1136/bmjopen-2020-037664